[go: up one dir, main page]

PE20081510A1 - Derivados de dihidropiridina como inhibidores de la proteina quinasa - Google Patents

Derivados de dihidropiridina como inhibidores de la proteina quinasa

Info

Publication number
PE20081510A1
PE20081510A1 PE2007001781A PE2007001781A PE20081510A1 PE 20081510 A1 PE20081510 A1 PE 20081510A1 PE 2007001781 A PE2007001781 A PE 2007001781A PE 2007001781 A PE2007001781 A PE 2007001781A PE 20081510 A1 PE20081510 A1 PE 20081510A1
Authority
PE
Peru
Prior art keywords
amino
alkyl
indazol
dihydro
dimethyl
Prior art date
Application number
PE2007001781A
Other languages
English (en)
Inventor
Guido Adler
Stefan Baeurle
Judi Bryant
Ming Chen
Yuo-Ling Chou
Paul Hrvatin
Seock-Kyu Khim
Monica J Kochanny
Wheeseong Lee
Michael Mamounas
Janet Meurer
Gary Bruce Phillips
Victor Selchau
Christopher West
Bin Ye
Shendong Yuang
Martin Krueger
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39262588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081510(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of PE20081510A1 publication Critical patent/PE20081510A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

REFERIDA A UN DERIVADO DE DIHIDROPIRIDINA DE FORMULA (I), DONDE R1 ES H, ALQUILO C1-C12, HALOALQUILO C1-C12, HIDROXIALQUILO C1-C12, ENTRE OTROS; R2 SE SELECCIONA DE R2-1, R2-2, R2-3 O R2-4; A Y B SON CR11 O N; D Y E SON NR12 O S; W, Y, X Y Z SON CR11, CR14 O N; n ES 1, 2 O 3; R3 ES H, CIANO, ALQUILO C1-C12, ENTRE OTROS; R4 ES HALOALQUILO C1-C2, ARILO, HETEROARILO, ENTRE OTROS; R5 ES H, ARALQUILO, R7, ENTRE OTROS; R6 ES ALQUILO C1-C3 O AMINO; R7 ES ALQUILO C1-C12, CICLOALQUILO, ARILO, ENTRE OTROS; R11 ES H, HALO, AMINO, NHC(=O)R7, ENTRE OTROS; R12 ES H, AMINO, ALQUILO C1-C12, ENTRE OTROS; R14 ES H, HALO, AMINO, NHR7, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 1,4-DIHIDRO-4-(1H-INDAZOL-5-IL)-2,6-DIMETIL-3,5-PIRIDINDICARBONITRILO, 4-(3-AMINO-1H-INDAZOL-5-IL)-1,4-DIHIDRO-2,6-DIMETIL-3,5-PIRIDINDICARBONITRILO, 1,4-DIHIDRO-4-[3-(3-METOXIFENIL)-1H-INDAZOL-5-IL]-2,6-DIMETIL-3,5-PIRIDINCARBONITRILO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UN PROCESO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE PROTEINA TIROSINA QUINASAS, PARTICULARMENTE, C-TET QUINASA Y SON UTILES EN EL TRATAMIENTO DE CANCERES
PE2007001781A 2006-12-14 2007-12-13 Derivados de dihidropiridina como inhibidores de la proteina quinasa PE20081510A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87512406P 2006-12-14 2006-12-14

Publications (1)

Publication Number Publication Date
PE20081510A1 true PE20081510A1 (es) 2008-12-12

Family

ID=39262588

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001781A PE20081510A1 (es) 2006-12-14 2007-12-13 Derivados de dihidropiridina como inhibidores de la proteina quinasa

Country Status (31)

Country Link
US (1) US8198456B2 (es)
EP (1) EP2121608B1 (es)
JP (2) JP2010513231A (es)
KR (1) KR20090087919A (es)
CN (1) CN101558040B (es)
AR (1) AR064349A1 (es)
AU (1) AU2007331676A1 (es)
BR (1) BRPI0719991A2 (es)
CA (1) CA2672167C (es)
CL (1) CL2007003609A1 (es)
CO (1) CO6210730A2 (es)
CR (1) CR10868A (es)
CU (1) CU23828B1 (es)
DO (1) DOP2009000141A (es)
EA (1) EA200900779A1 (es)
EC (1) ECSP099414A (es)
ES (1) ES2396160T3 (es)
HN (1) HN2009001165A (es)
IL (1) IL198171A0 (es)
MA (1) MA31090B1 (es)
MX (1) MX2009006267A (es)
MY (1) MY148851A (es)
NO (1) NO20092651L (es)
NZ (1) NZ577611A (es)
PE (1) PE20081510A1 (es)
SG (1) SG177200A1 (es)
SV (1) SV2009003299A (es)
TN (1) TN2009000128A1 (es)
TW (1) TW200836729A (es)
UY (1) UY30779A1 (es)
WO (1) WO2008071451A1 (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110301155A1 (en) * 2007-06-19 2011-12-08 Tsuneo Yasuma Indazole compounds for activating glucokinase
ATE540042T1 (de) * 2008-06-09 2012-01-15 Bayer Pharma AG Annelierte 4-(indazolyl)-1,4- dihydropyridinderivate als c-met-mediatoren
EP2294062B1 (en) 2008-06-09 2013-08-21 Bayer Intellectual Property GmbH Substituted 4- (indazolyl) -1,4-dihydropyridines and methods of use thereof
EP2398790B1 (en) * 2009-02-18 2013-07-03 Bayer Intellectual Property GmbH Bi- and tricyclic indazole-substituted 1,4-dihydropyridine derivatives and uses thereof
CN102639537B (zh) * 2009-07-10 2015-07-22 拜耳知识产权有限责任公司 吲唑基取代的二氢异*唑并吡啶及其使用方法
WO2011019651A1 (en) 2009-08-10 2011-02-17 Epitherix, Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
JP2011057661A (ja) * 2009-08-14 2011-03-24 Bayer Cropscience Ag 殺虫性カルボキサミド類
WO2011042367A1 (en) 2009-10-06 2011-04-14 Bayer Schering Pharma Ag Fluorinated 2,6-dialkyl-3,5-dicyano-4-(1h-indazol-5-yl)-1,4-dihydropyridines and methods of use thereof
UY32922A (es) 2009-10-06 2011-04-29 Bayer Schering Pharma Ag Derivados de 3, 5-diciano-4-(1h-indazol-5-il)-2,6-dimetil-1,4-dihidropiridina fluoro-sustituidos y procedimientos de uso de los mismos
CA2777907C (en) * 2009-11-11 2017-08-29 Bayer Pharma Aktiengesellschaft Fluoro-substituted 2-aryl-3,5-dicyano-4-indazolyl-6-methyl-1,4-dihydropyridines and uses thereof
US8604028B2 (en) * 2009-11-18 2013-12-10 Bayer Intellectual Property Gmbh Furopyridinyl-substituted 1,4-dihydropyridine derivatives and methods of use thereof
DE102009056886A1 (de) 2009-12-03 2011-06-09 Bayer Schering Pharma Aktiengesellschaft cMet-Inhibitoren zur Behandlung der Endometriose
CA2784753A1 (en) 2009-12-18 2011-06-23 Janssen Pharmaceutica Nv Substituted aminothiazolone indazoles as estrogen related receptor-.alpha. modulators
RS56669B1 (sr) 2009-12-21 2018-03-30 Samumed Llc 1h-pirazolo[3,4-b]piridini i njihove terapeutske primene
US20130315895A1 (en) 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
MX2013006467A (es) 2010-12-09 2013-10-01 Amgen Inc Compuestos biciclicos como inhibidores pim.
EP2688886A1 (en) 2011-03-22 2014-01-29 Amgen Inc. Azole compounds as pim inhibitors
PT2755483T (pt) 2011-09-14 2019-02-18 Samumed Llc Indazol-3-carboxamidas e sua utilização como inibidores da via de sinalização de wnt/β-catenina
CN103204844A (zh) 2012-01-17 2013-07-17 上海艾力斯医药科技有限公司 氨基杂芳基化合物及其制备方法与应用
CN103319456B (zh) * 2012-03-23 2015-05-13 上海汇伦生命科技有限公司 二氢吡啶类化合物、其组合物、制备方法和用途
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
KR102223301B1 (ko) 2012-05-04 2021-03-05 사뮤메드, 엘엘씨 1H-피라졸로[3,4-b]피리딘 및 그의 치료 용도
CN105120862A (zh) 2013-01-08 2015-12-02 萨穆梅德有限公司 Wnt信号途径的3-(苯并咪唑-2-基)-吲唑抑制剂及其治疗应用
CA2905242C (en) 2013-03-15 2016-11-29 Pfizer Inc. Indole compounds that activate ampk
EP3089746A4 (en) 2013-12-30 2017-08-30 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
US9611252B2 (en) 2013-12-30 2017-04-04 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
JP6951970B2 (ja) * 2014-07-16 2021-10-20 ライフサイ ファーマシューティカルズ，インク． 治療用阻害化合物
WO2016040188A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040193A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040184A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040180A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040181A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040190A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040185A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
WO2016040182A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof
ES2764299T3 (es) 2014-12-09 2020-06-02 Inst Nat Sante Rech Med Anticuerpos monoclonales humanos contra AXL
WO2016135041A1 (en) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Fusion proteins and antibodies comprising thereof for promoting apoptosis
US10604512B2 (en) 2015-08-03 2020-03-31 Samumed, Llc 3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof
US10285982B2 (en) 2015-08-03 2019-05-14 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017024010A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
WO2017023984A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
WO2017024015A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10226453B2 (en) 2015-08-03 2019-03-12 Samumed, Llc 3-(1H-indol-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10206909B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023972A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017024025A1 (en) 2015-08-03 2017-02-09 Sunil Kumar Kc 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10231956B2 (en) 2015-08-03 2019-03-19 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10383861B2 (en) 2015-08-03 2019-08-20 Sammumed, LLC 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
US10166218B2 (en) 2015-08-03 2019-01-01 Samumed, Llc 3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017023987A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
WO2017023996A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
US10350199B2 (en) 2015-08-03 2019-07-16 Samumed, Llc 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
WO2017023989A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10188634B2 (en) 2015-08-03 2019-01-29 Samumed, Llc 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
KR20180080262A (ko) 2015-11-06 2018-07-11 사뮤메드, 엘엘씨 골관절염의 치료
US20190016680A1 (en) 2016-01-14 2019-01-17 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
ES2962315T3 (es) 2016-04-20 2024-03-18 Bristol Myers Squibb Co Compuestos heterocíclicos bicíclicos sustituidos
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
JP7010851B2 (ja) 2016-06-01 2022-02-10 バイオスプライス セラピューティクス インコーポレイテッド Ｎ－（５－（３－（７－（３－フルオロフェニル）－３Ｈ－イミダゾ［４，５－ｃ］ピリジン－２－イル）－１Ｈ－インダゾール－５－イル）ピリジン－３－イル）－３－メチルブタンアミドを調製するための方法
WO2018011628A1 (en) 2016-07-11 2018-01-18 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
KR102593742B1 (ko) 2016-10-21 2023-10-24 사뮤메드, 엘엘씨 인다졸-3-카복사마이드를 사용하는 방법 및 wnt/b-카테닌 신호전달 경로 억제제로서의 그들의 용도
US10758523B2 (en) 2016-11-07 2020-09-01 Samumed, Llc Single-dose, ready-to-use injectable formulations
EP3480201A1 (en) * 2017-11-06 2019-05-08 Oncostellae, S.L. New analogs as androgen receptor and glucocorticoid receptor modulators
WO2019180141A1 (en) 2018-03-23 2019-09-26 Bayer Aktiengesellschaft Combinations of rogaratinib
EP3774769A1 (en) 2018-03-28 2021-02-17 Bayer Pharma Aktiengesellschaft 4-(3-amino-6-fluoro-1h-indazol-5-yl)-1,2,6-trimethyl-1,4-dihydropyridine-3,5-dic arbonitrile compounds for treating hyperproliferative disorders
CN110078707A (zh) * 2019-06-03 2019-08-02 上海贤鼎生物科技有限公司 一种2-(1H-苯并[d]咪唑-2-基)-8-羟基喹啉的合成方法
CN116969891A (zh) * 2023-07-28 2023-10-31 杭州国瑞生物科技有限公司 一种7-甲基-5-醛基-1h-吲唑的合成方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS162291B1 (es) * 1973-04-26 1975-07-15
PL86477B1 (es) * 1973-09-01 1976-05-31
CS168272B1 (es) * 1973-09-18 1976-05-28
GB1457787A (en) * 1974-05-17 1976-12-08 Wyeth John & Brother Ltd Dihydropyridines
CS191511B1 (en) * 1976-09-06 1979-07-31 Jaroslav Palecek Process for preparing 1-dialkylaminoalkyl-2,6-dimethyl-4-/y-substituted phenyl/-3,5-disubstituted 1,4-dihydropyridines
GB9515445D0 (en) * 1995-07-27 1995-09-27 Pharmacia Spa Dihydropyridine and pyridine derivatives and process for their preparation
US6265127B1 (en) * 1999-12-15 2001-07-24 Eastman Kodak Company 1, 4-dihydrophyridine charge control agents for electrostatographic toners and developers
US6790852B2 (en) 2002-04-18 2004-09-14 Hoffmann-La Roche Inc. 2-(2,6-dichlorophenyl)-diarylimidazoles
DK2476667T3 (da) 2003-02-26 2014-09-15 Sugen Inc Aminoheteroaryl-forbindelser som proteinkinase-inhibitorer
WO2005005378A2 (en) 2003-07-02 2005-01-20 Sugen, Inc. Indolinone hydrazides as c-met inhibitors
JP2007230869A (ja) * 2004-04-05 2007-09-13 Takeda Chem Ind Ltd アルドステロン受容体拮抗剤
SI1784396T1 (sl) 2004-08-26 2011-03-31 Pfizer S pirazolom substituirane aminoheteroarilne spojine kot zaviralci protein-kinaze
ES2390227T3 (es) * 2004-09-09 2012-11-07 Natco Pharma Limited Nuevos derivados de fenilaminopirimidina como inhibidores de la BCR-ABL kinasa
WO2006066011A2 (en) 2004-12-13 2006-06-22 Irm Llc Compounds and compositions as modulators of steroidal receptors and calcium channel activities
CA2603676A1 (en) * 2005-01-07 2006-07-13 Roskamp Research Llc Compounds for inhibiting beta-amyloid production and methods of identifying the compounds
AU2007240496A1 (en) * 2006-04-19 2007-11-01 Novartis Ag Indazole compounds and methods for inhibition of CDC7

Also Published As

Publication number Publication date
ES2396160T3 (es) 2013-02-19
CR10868A (es) 2009-07-23
ES2396160T8 (es) 2013-03-22
MY148851A (en) 2013-06-14
WO2008071451A1 (en) 2008-06-19
HN2009001165A (es) 2011-11-03
TW200836729A (en) 2008-09-16
CL2007003609A1 (es) 2008-07-25
HK1135103A1 (en) 2010-05-28
SV2009003299A (es) 2009-12-14
MA31090B1 (fr) 2010-01-04
US8198456B2 (en) 2012-06-12
UY30779A1 (es) 2008-07-31
NO20092651L (no) 2009-09-14
DOP2009000141A (es) 2009-07-15
IL198171A0 (en) 2009-12-24
EA200900779A1 (ru) 2010-02-26
JP2014139197A (ja) 2014-07-31
CA2672167A1 (en) 2008-06-19
KR20090087919A (ko) 2009-08-18
EP2121608A1 (en) 2009-11-25
JP2010513231A (ja) 2010-04-30
US20080176833A1 (en) 2008-07-24
CN101558040A (zh) 2009-10-14
AU2007331676A1 (en) 2008-06-19
CU23828A3 (es) 2012-06-29
JP6021838B2 (ja) 2016-11-09
CN101558040B (zh) 2013-03-27
AR064349A1 (es) 2009-04-01
EP2121608B1 (en) 2012-11-14
CO6210730A2 (es) 2010-10-20
TN2009000128A1 (en) 2010-10-18
CU20090107A7 (es) 2012-02-15
BRPI0719991A2 (pt) 2014-03-18
CA2672167C (en) 2016-01-26
NZ577611A (en) 2012-01-12
ECSP099414A (es) 2009-07-31
CU23828B1 (es) 2012-06-29
MX2009006267A (es) 2009-06-22
SG177200A1 (en) 2012-01-30

Similar Documents

Publication Publication Date Title
PE20081510A1 (es) Derivados de dihidropiridina como inhibidores de la proteina quinasa
PE20090884A1 (es) Compuestos de indol como activadores de glucoquinasa
PE20041078A1 (es) Derivados heterociclicos inhibidores de la elastasa leucocitica humana (elh)
AR055360A1 (es) Inhibidores macrociclicos del virus de la hepatitis c
PE20100138A1 (es) Derivados de morfolino pirimidina usados en enfermedades relacionadas en mtor quinasa y/o pi3k
PE20081362A1 (es) DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K
PE20060374A1 (es) Inhibidores de cinasa heterociclicos fusionados
PE20080677A1 (es) Inhibidores de pirrolotriazina cinaza
PE20091466A1 (es) Derivados de 4,5-dihidro-oxazol-2-il-amina
PE20060197A1 (es) Heterociclos biciclicos como inhibidores de cinasa
PE20090160A1 (es) COMPUESTOS AMINO-5-[4-(DIFLUOROMETOXI)FENIL SUSTITUIDO]-5-FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA
TW200800949A (en) Macrocylic inhibitors of hepatitis C virus
PE20080925A1 (es) DERIVADOS DE PIRROLO[2,3-b]PIRIDINA COMO INHIBIDORES DE QUINASA, EN PARTICULAR INHIBIDORES IKK2 (O IKK BETA)
PE20061436A1 (es) Derivados de amida sustituida como inhibidores de proteina quinasa
PE20080005A1 (es) Derivados de cromanol sustituidos como agentes inhibidores de cetp
EA200970493A1 (ru) Макроциклические ингибиторы вируса гепатита с
PE20150621A1 (es) Derivados de 2,4-diamino-pirimidina n2, n4-disustituidos como inhibidores de jak3
PE20060625A1 (es) Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina
PE20141681A1 (es) Inhibidores de btk
PE20090617A1 (es) Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa
PE20061106A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
DE602005024239D1 (de) Pyrimidin-verbindungen als purin-rezeptorantagonisten
PE20091849A1 (es) Compuestos y composiciones como inhibidores de cinasa
AR053301A1 (es) Derivados de pirazina y su uso farmaceutico
ATE388146T1 (de) 1-isopropyl-2-oxo-1,2-dihydropyridin-3- carbonsäureamidderivate mit agonistischer wirkung am 5-ht4-rezeptor

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed